<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680689</url>
  </required_header>
  <id_info>
    <org_study_id>CM0520-FUSEH</org_study_id>
    <nct_id>NCT04680689</nct_id>
  </id_info>
  <brief_title>Assessment of Lesion-Associated Myocardial Ischemia Based on Fusion Coronary CT Imaging</brief_title>
  <acronym>FUSE-HEART</acronym>
  <official_title>Assessment of Lesion-Associated Myocardial Ischemia Based on Fusion Coronary CT Imaging- the FUSE-HEART Study: Protocol for a Non-randomised Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardio Med Medical Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>George Emil Palade University of Medicine, Pharmacy, Sciences and Technology of Targu Mures</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tîrgu Mureș Emergency Clinical County Hospital, Romania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardio Med Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the Fused-Heart study is to investigate the impact of a coronary artery stenosis&#xD;
      on myocardial function and viability, based on advanced fusion imaging techniques derived&#xD;
      from CCTA.&#xD;
&#xD;
      Moreover the study will investigate the correlation between morphology and composition of&#xD;
      atheromatous plaques located in a coronary artery and myocardial ischemia in the territory&#xD;
      irrigated by the same coronary artery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The FUSE-HEART study is a prospective, observational, single-center, cohort study that will&#xD;
      be conducted in the Laboratory of Advanced Research in Cardiac Multimodal Imaging of Cardio&#xD;
      Med Medical Center Targu Mures, Romania.&#xD;
&#xD;
      The study will include 100 subjects with coronary lesions depicted by CCTA examination. The&#xD;
      study population will consist in: (1) patients with anatomically significant coronary lesions&#xD;
      (at least 50% luminal narrowing) on native coronary arteries, or (2) patients surviving an&#xD;
      acute myocardial infarction, revascularized or not. In all patients, presence of&#xD;
      vulnerability features in the atheromatous plaques will be studied and the vulnerability&#xD;
      score will be calculated for each plaque, consisting in one point added for each of the&#xD;
      following vulnerability markers: positive remodeling, napkin-rink sign, presence of low&#xD;
      density plaque or spotty calcium within the plaque. In addition, following 3D fusion of the&#xD;
      images of the coronary tree with the images reflecting wall motion, the correspondence&#xD;
      between plaque morphology and composition on one hand, and wall motion in the corresponding&#xD;
      distribution territory of that coronary artery, will be studied based on fused models.&#xD;
&#xD;
      The study will be conducted over a period of 2 years, in which patients will be examined at&#xD;
      baseline, with a projected recruitment period of 1 year and will be followed-up 1 year for&#xD;
      MACE.&#xD;
&#xD;
      Study objectives:&#xD;
&#xD;
      Primary: to investigate the impact of a coronary artery stenosis on myocardial function and&#xD;
      viability, based on advanced fusion imaging techniques derived from CCTA.&#xD;
&#xD;
      Secondary: to investigate the correlation between morphology and composition of atheromatous&#xD;
      plaques located in a coronary artery and myocardial ischemia in the territory irrigated by&#xD;
      the same coronary artery.&#xD;
&#xD;
      Study timeline:&#xD;
&#xD;
      • Baseline (day 0)-Obtain and document consent from participant on study consent form.&#xD;
&#xD;
      Verify inclusion/exclusion criteria. Obtain demographic information, medical history,&#xD;
      medication history, alcohol and tobacco use history. Record results of physical examinations&#xD;
      and 12-lead ECG.Collect blood specimens (complete blood count, biochemistry and inflammatory&#xD;
      biomarkers).Imaging procedures: CCTA-Image processing - quantification of coronary stenosis,&#xD;
      characterization of vulnerability markers, 3D reconstruction, extension and characterization&#xD;
      of wall motion. Deliver fused 3D images&#xD;
&#xD;
      • Visit 1 (month 1)-Record results of physical examinations, 12-lead ECG, blood pressure, and&#xD;
      medical history. MACE assessment Visit 2 (month 3) -Telephone visit with target questions,&#xD;
      all the answers recorded in study forms Visit 3 (month 6) - Record results of physical&#xD;
      examinations, 12-lead ECG, blood pressure, and medical history. MACE assessment&#xD;
&#xD;
      Final study visit (month 12)- Record results of physical examinations, medical&#xD;
      history,12-lead ECG, blood pressure, transthoracic 2-D echocardiography. End-point and MACE&#xD;
      evaluation.&#xD;
&#xD;
      Study procedures:&#xD;
&#xD;
        -  Medical history, clinical examination, laboratory tests (complete blood count,&#xD;
           biochemistry, inflammatory biomarkers: hs-CRP, MMP, IL6 and NT-pro-BNP);&#xD;
&#xD;
        -  12-lead ECG&#xD;
&#xD;
        -  2D transthoracic echocardiography&#xD;
&#xD;
        -  CCTA&#xD;
&#xD;
        -  Computerized postprocessing and fused images&#xD;
&#xD;
      Data collection:&#xD;
&#xD;
      All the information will be collected in a dedicated database including medical history,&#xD;
      medication, imaging features provided by cardiac ultrasound, CCTA and fused images resulting&#xD;
      from imaging post-processing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MACE rate-Major Adverse Cardiovascular Events</measure>
    <time_frame>12 months</time_frame>
    <description>The primary outcome of the study is represented by the rate of MACE events related to myocardial ischemia at 1-year post assessment, in correlation with the degree of coronary artery stenosis and myocardial ischemia or viability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalisation rate,</measure>
    <time_frame>12 months</time_frame>
    <description>Secondary outcome refers to rate of re-hospitalization, in correlation with the morphology and composition of atheromatous plaques located in a coronary artery and myocardial ischemia in the territory irrigated by the same coronary artery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of survival</measure>
    <time_frame>12 months</time_frame>
    <description>This outcome refers to rate of survival in correlation with the morphology and composition of atheromatous plaques located in a coronary artery and myocardial ischemia in the territory irrigated by the same coronary artery</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myocardial Ischemia</condition>
  <condition>Myocardial Viability</condition>
  <condition>Coronary Stenosis</condition>
  <condition>Vulnerable Coronary Plaques</condition>
  <arm_group>
    <arm_group_label>Fuse-Heart -SG 01</arm_group_label>
    <description>Study subjects with anatomically significant coronary lesions (at least 50% luminal narrowing) on native coronary arteries.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fuse-Heart -SG 02</arm_group_label>
    <description>Study subjects surviving an acute myocardial infarction, revascularized or not.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>128 Multislice CT coronary angiography</intervention_name>
    <description>128 Multislice CT coronary angiography with the evaluation of coronary stenosis, the plaque vulnerability markers ( necrotic core, low attenuation plaque, spotty calcifications, napkin ring sign, positive remodeling), asses polar maps of the myocardium</description>
    <arm_group_label>Fuse-Heart -SG 01</arm_group_label>
    <arm_group_label>Fuse-Heart -SG 02</arm_group_label>
    <other_name>CCTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>2D Cardiac Transthoracic Echocardiography</intervention_name>
    <description>2D Cardiac Transthoracic Echocardiography with the evaluation of the cardiac cavity dimensions</description>
    <arm_group_label>Fuse-Heart -SG 01</arm_group_label>
    <arm_group_label>Fuse-Heart -SG 02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Laboratory Blood tests</intervention_name>
    <description>Laboratory tests for evaluations the level of inflammatory biomarkers ( hs-CRP, MMP, IL6 and NT-pro-BNP), complete blood count, biochemestry</description>
    <arm_group_label>Fuse-Heart -SG 01</arm_group_label>
    <arm_group_label>Fuse-Heart -SG 02</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      venous blood samples for complete blood count, biochemistry, inflammatory biomarkers&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study will include 100 subjects with coronary lesions depicted by CCTA examination. The&#xD;
        study population will consist in: (1) patients with anatomically significant coronary&#xD;
        lesions (at least 50% luminal narrowing) on native coronary arteries, or (2) patients&#xD;
        surviving an acute myocardial infarction, revascularized or not.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing CCTA examination, with at least one coronary artery lesion&#xD;
             producing a luminal narrowing &gt;50%&#xD;
&#xD;
          -  Ability to provide informed consent;&#xD;
&#xD;
          -  Patients aged at least 18 years;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwillingness or incapacity to provide informed consent;&#xD;
&#xD;
          -  Allergy to contrast media;&#xD;
&#xD;
          -  Absolute or relative contraindications to CCTA imaging;&#xD;
&#xD;
          -  Irregular or rapid heart rhythm&#xD;
&#xD;
          -  Pregnancy or lactation;&#xD;
&#xD;
          -  Women with childbearing potential in absence of any contraceptive treatment;&#xD;
&#xD;
          -  Renal insufficiency (creatinine greater than 1.5 mg/dL) or renal failure requiring&#xD;
             dialysis;&#xD;
&#xD;
          -  Active malignancy or malignancy within the last 5 year prior to enrollment;&#xD;
&#xD;
          -  Conditions associated with an estimated life expectancy of under 2 years;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Gorea Stanescu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardio Med</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theodora Benedek, Prof</last_name>
    <phone>0722560549</phone>
    <email>theodora.benedek@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Imre Benedek, Prof</last_name>
    <phone>0744626546</phone>
    <email>imrebenedek@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardio Med Medical Center</name>
      <address>
        <city>Targu Mures</city>
        <state>Mures</state>
        <zip>540102</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fusion imaging</keyword>
  <keyword>CCTA</keyword>
  <keyword>Myocardial viability</keyword>
  <keyword>Vulnerable coronary plaques</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication will be available for interested parties</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The IPD sharing time is starting 6 months aflter publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

